SCWorx (WORX) EBITDA Margin (2015 - 2026)

SCWorx (WORX) posted EBITDA Margin of 18.23% for Q1 2026, up 27.11% sequentially from 25.01% in Q4 2025, and up 2814.0% YoY from 0.63% in Q1 2025.

SCWorx (WORX) EBITDA Margin (2015 - 2026) Analysis & Trends

SCWorx has reported EBITDA Margin for 12 years, with the latest figure at 18.23% in Q1 2026.

Quarterly EBITDA Margin rose 2814.0% year-over-year to 18.23% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26.21% (up 2262.0% YoY) and the FY2025 annual result came in at 33.32%, up 881.0% from the prior year.
EBITDA Margin improved to 18.23% in Q1 2026 per WORX's latest filing, from 25.01% in the prior quarter.
Over five years, EBITDA Margin peaked at 4.92% in Q4 2023 and troughed at 94.69% in Q3 2023.
A 5-year average of 40.52% and a median of 41.39% in 2024 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2022 and 2024: EBITDA Margin surged 5690 bps in 2022, then sank 5136 bps in 2024.
Over 5 years, EBITDA Margin stood at 24.79% in 2022, then jumped by 80 bps to 4.92% in 2023, then slumped by 1044 bps to 56.28% in 2024, then soared by 56 bps to 25.01% in 2025, then gained by 27 bps to 18.23% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 18.23%, 25.01%, and 19.67% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Veeva Systems	39.72 Bn	32.40 Bn	662.02 Mn	30.93%
2	BrightSpring Health Services	12.19 Bn	11.64 Bn	492.75 Mn	3.37%
3	Healthequity	8.79 Bn	8.52 Bn	256.31 Mn	29.03%
4	10x Genomics	7.31 Bn	6.76 Bn	112.50 Mn	-12.95%
5	Hinge Health	7.10 Bn	6.71 Bn	183.95 Mn	19.00%
6	MiniMed	5.66 Bn	5.36 Bn	480.00 Mn	-11.11%
7	Waystar Holding	4.76 Bn	4.56 Bn	221.99 Mn	23.79%
8	Doximity	4.46 Bn	3.77 Bn	132.93 Mn	21.48%
9	Heartflow	3.66 Bn	3.28 Bn	53.19 Mn	-27.93%
10	SCWorx	5.87 Mn	4.53 Mn	330,423.00	-17.13%

Download Data